Based on the most recent recommendations from the American College of Cardiology (ACC), it is recommended to prescribe mineralocorticoid receptor antagonists (MRAs) to all symptomatic heart failure with reduced ejection fraction (HFrEF) patients who do not have contraindications [3]. This evidence concerns the gene NR3C2 and heart failure.